The manufactured COVID pandemic has been a proverbial golden egg-laying goose for Pfizer. Its annual revenue is expected to reach $ 101.3 billion in 2022,1 thanks to its COVID jab, which doesn’t prevent infection or spread, and Paxlovid, an ineffective and dangerous COVID antiviral that causes rebound. It would be comical if it weren’t so… Read More »
In a first for the U.S., the FDA has authorized the use of Pfizer’s BioNTech-partnered COVID-19 vaccine for use in adolescents between the ages of 12 and 15—months ahead of the upcoming school year in the fall. The FDA will amend the existing emergency authorization for the vaccine, which was first issued in December, the agency said. Pfizer’s… Read More »
After Pfizer’s Ibrance failed a crucial study in HR-positive, HR-negative postsurgery breast cancer patients, the company clung to hope that it could still show a benefit in a high-risk subset of those patients. But new data have officially snuffed out those hopes. There’s “no saving adjuvant for Ibrance,” SVB Leerink analyst Geoffrey Porges wrote in… Read More »